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Abstract
Homing is an inherent, complex, multistep process performed by cells such as human bone marrow mesenchymal stem cells
(hMSCs) to travel from a distant location to inflamed or damaged tissue and tumors. This ability of hMSCs has been exploited as a
tumor-targeting strategy in cell-based cancer therapy. The purpose of this study was to investigate the applicability of 111In-oxine for
tracking hMSCs in vivo by combining single-photon emission computed tomography (SPECT) and magnetic resonance imaging
(MRI). 111In-labeled hMSCs (106 cells) were infused intraperitoneally in neuroblastoma-bearing mice, whereas a control group
received a dose of free 111In-oxine. SPECT and MRI studies were performed 24 and 48 hours afterwards. Initially, the images showed
similar activity in the abdomen in both controls and hMSC-injected animals. In general, abdominal activity decreases at 48 hours.
hMSC-injected animals showed increased uptake in the tumor area at 48 hours, whereas the control group showed a low level of
activity at 24 hours, which decreased at 48 hours. In conclusion, tracking 111In-labeled hMSCs combining SPECT and MRI is feasible
and may be transferable to clinical research. The multimodal combination is essential to ensure appropriate interpretation of the
images.
H UMAN MESENCHYMAL STEM CELLS (hMSCs)are present in bone marrow niches. They can
differentiate into cells of the mesodermal lineage (e.g.,
osteoblasts, adipocytes, and chondrocytes) and have the
intrinsic ability to respond by migrating to damaged or
inflamed tissues.1,2 In this regard, hMSCs have been used to
regenerate injured tissue (e.g., infarcted myocardium) in
animals and patients.3,4 hMSCs are also capable of homing
to several types of tumors, including glioma, carcinoma
(breast, colon, and lung), leukemia, and many types of
metastatic tumors. Depending on the tumor microenviron-
ment, hMSCs can display antitumoral properties, such as
decreasing cancer cell growth, or protumoral properties,
such as promoting metastasis or suppression of the immune
response.5,6
In this work, we assessed the ability of injected cells to
actively home to tumors, which supports the use of hMSCs
as therapeutic vehicles to deliver anticancer agents. Garcia-
Castro and colleagues showed that hMSCs irradiated
and infected with oncolytic adenoviruses (CELYVIR) can
be used as an effective therapy against metastatic and
refractory neuroblastoma in children.7 A complete clinical
response was documented in one case. In that study, the
number of metastases decreased, suggesting adenovirus
activity because of hMSC homing. In our study, we used
an imaging-based animal model to verify that hMSCs
migrate to the neuroblastoma. Our approach can thus be
transferred to human studies.
Migration of hMSCs can be tracked using mole-
cular imaging modalities. Besides genetic modification,
hMSCs can be labeled with different radiotracers (99mTc–
hexamethylpropyleneamine oxime [HMPAO], 111In-oxine,
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and [18F]fluorodeoxyglucose [FDG]), (ultrasmall) super-
paramagnetic iron oxide (SPIO) particles, and quantum
dots. The use of the corresponding imaging modality
provides noninvasive methods for tracking and quantifying
the fate of hMSCs administered in vivo, although not all
available procedures are applicable to humans.6,8 de Vries
and colleagues demonstrated that magnetic resonance
imaging (MRI) is at least as sensitive as scintigraphy for
detecting dendritic cell migration after intranodal coinjec-
tion of an equal number of 111In-oxine– and SPIO-labeled
cells in patients.9 However, given that the use of SPIO
compounds in humans is restricted because of safety
concerns, transferring this approach from animal models
will remain problematic until better methods of introducing
SPIOs into nonphagocytic cells are developed.9,10
Although many strategies are able to label and track
stem cells in vivo,11 only 111In-oxine and 99mTc-HMPAO
are currently approved as clinical procedures (indicated for
the detection of infections and inflammation by labeling
leukocytes).12 One obvious disadvantage of nuclear
imaging is its potential effect on cell viability and
proliferation. On the other hand, nuclear imaging offers
better sensitivity, tissue penetration, and quantitative
properties than optical imaging and MRI. 111In-labeled
cells have been used for many years to track leukocytes and
thus localize inflammatory processes in patients. Chin and
colleagues studied the biodistribution of 111In-oxine–labeled
swine MSCs 14 days after administration.13 111In-labeled
MSCs have also been applied in several preclinical settings:
myocardial accumulation after intravenous administration
in a swine myocardial infarction model,13 dynamic distribu-
tion to different organs after infusion through different
portals in healthy rats,14 and analyses of the effects of 111In-
labeled MSCs on cell proliferation, differentiation, and
viability.2,15 In contrast to 111In-oxine, 99mTc-HMPAO
could be administered at higher doses to improve image
quality. However, its radiolabeling efficiency is poor because
its retention within the cells is lower than that of 111In-
oxine.16 The short half-life of FDG (2 hours) reduces its
applications in longitudinal studies.17 Some novel techni-
ques, such as direct 89Zr-oxine labeling, have shown good
preliminary results.18,19 Besides the improvement in spatial
resolution from single-photon emission computed tomo-
graphy (SPECT) to positron emission tomography (PET),
89Zr-oxine imaging also needs 10 times lower activity
compared to 111In-oxine. However, the 89Zr-oxine labeling
protocol has some disadvantages compared to 111In-
oxine.19 For instance, Meszaros and colleagues showed that
89Zr-oxine labeling efficiency was 2.5 times lower in 5T33
myeloma cells compared to 111In-oxine.18
Over the last decade, MRI has been emerged as a
powerful tool for preclinical cell tracking due to its high
spatial resolution. In some scenarios, the anatomic
resolution may render this technique more suitable than
SPECT, when the cells are directly injected into the target
area.9 Nevertheless, with intravenous administration, MRI
is not yet as sensitive as SPECT.20
Multimodality imaging using separate scanners requires
very careful transfer of the animal followed by image
coregistration. Some authors used SPECT–computed
tomography (CT) systems,15,20 although MRI provides
much better anatomic detail. Alignment accuracy depends
on the resolution of both modalities and on possible image
artifacts. Our small-animal SPECT studies have a spatial
resolution of about 1 mm3. To facilitate SPECT/MRI
coregistration, we used an in-house multimodality bed
combined with a semiautomated rigid registration method
based on matching lines.21 The approach resulted in target
registration errors close to the SPECT spatial resolution
(, 0.9 mm). In terms of accuracy, our registration results
are consistent with those reported in the literature.22
Despite the availability of several methods for coregistering
SPECT and MRI images,22,23 we did not find references to
coregistering SPECT and MRI in cell-tracking experiments,
where activity at the target can be very low and accurate
spatial registration is required. A hybrid system (SPECT-
MRI or PET-MRI) would facilitate this kind of approach.
The purpose of our work was to use a multimodality
approach combining the sensitivity of SPECT with the
anatomic reliability of MRI to detect hMSC homing in
neuroblastoma-bearing mice.
Material and Methods
Ethics Statement
All animal procedures were approved by the Animal
Experimentation Ethics Committee of Hospital General
Universitario Gregorio Maran˜o´n (ES280790000087) and
were performed according to European Union directive
(2010/63/EU) and national regulations (RD 53/2013). All
human procedures were approved by the Clinical Research
Ethics Committee of Hospital Universitario Nin˜o Jesus
(Madrid, Spain), and written informed consent was
obtained from all participants (R-0030/09).
Cell Isolation, Culture, and Characterization
hMSCs were obtained following a previously described
protocol7 from three different donors. Briefly, mononuclear
2 Cusso´ et al
cells were isolated from bone marrow aspirates using Ficoll
density centrifugation, resuspended in MSC medium
(Dulbecco’s Modified Eagle’s Medium [DMEM] plus 10%
fetal bovine serum), seeded into culture flasks at 3 3 104
cells/cm2, and allowed to adhere. After the fourth passage, a
homogeneous hMSC culture was obtained and character-
ized according to the criteria of the International Society for
Cellular Therapy.24 Cells were frozen at 1.8 3 106 per
milliliter after the fifth passage.
The human neuroblastoma cell line NB-1691 was
derived from a neuroblastoma in a pediatric patient at
Hospital Universitario Nin˜o Jesu´s. Cells were cultured in
monolayer at 37uC with 5% CO2 in DMEM (Lonza,
Switzerland) supplemented with 10% fetal bovine serum
(PAN-Biotech GmbH, Germany).
111In-Oxine Labeling
Cells were labeled following the protocol of Gildehaus and
colleagues.15 Briefly, cells were thawed and centrifuged at
1,800 rpm for 5 minutes, and the cell pellet was resuspended
with 10 Bq/cell 111In-oxine in 1 mL of phosphate-buffered
saline (PBS) and incubated for 20 minutes at 37uC. Cells
were then washed twice with PBS, and the activity of the
supernatants and cell pellet (after PBS washes) was
measured in an activimeter (Capintec CRC, USA). The
labeling yield was calculated by dividing cell activity by total
activity (activity in cells and in supernatant). For admin-
istration, around 1 million 111In-labeled hMSCs per animal
were separated and resuspended in 0.5 mL PBS with heparin
(1 unit per 0.1 mL). The solution was visually inspected to
avoid clumps or aggregates.
Animals
Orthotopic human tumor xenografts are an excellent model
for predicting physiologic and treatment response in human
tumors.25 For this reason, we developed a xenograft model
in NOD/SCID male immunodeficient mice. Nine animals
received one subcutaneous injection of 2.5 3 106 NB-1691
cells (resuspended in 100 mL of PBS/injection) in the left
hind flank. The NB-1691 cell line was selected because
tumor-secreted chemokines are more similar to those
secreted by human neuroblastoma tumors.26
Three weeks after tumor implantation, seven mice
received an intraperitoneal dose of 1 million 111In-labeled
hMSCs (hMSC-injected animals) in 0.5 mL PBS. Two
control animals received an equivalent intraperitoneal dose
of free 111In-oxine. Both 111In-labeled hMSCs and free
111In-oxine were injected when labeling was finished to
avoid cell damage or radiopharmaceutical degradation.
hMSCs were injected intraperitoneally in the right upper
abdominal quadrant to maximize the distance to the
tumor.
SPECT/MRI
Multimodality imaging was performed with a small-animal
SPECT scanner (mSPECT, MILabs, the Netherlands) and a
preclinical MRI system (7T Biospin, Bruker, Germany).
SPECT and MRI images were acquired 24 and 48 hours after
administration of 111In-labeled hMSCs or free 111In-oxine.
To coregister the SPECT and MRI images, each animal was
placed on an in-house multimodal bed surrounded by three
noncoplanar capillaries filled with a mixture of 99mTc and
CuSO4, which was visible in both modalities. The use of
different SPECT radionuclides for the fiducials allowed us to
separately reconstruct the capillaries and animal images
using the respective radioisotope photopeaks (140 keV for
99mTc and 171 + 245 keV for 111In). This procedure allows
for good visualization of the capillaries while preventing
spillover from the fiducials into the tumor region.
The SPECT acquisition parameters were an isotropic
voxel size of 0.4 mm and an acquisition time of 1.5 to
2 hours. SPECT images were reconstructed using two-
dimensional ordered subset expectation maximization
(OSEM-2D) with 16 subsets and 1 iteration. The MRI was
obtained immediately after completion of SPECT imaging.
A coronal MRI was acquired using a turbo rapid acquisition
with refocused echo (turboRARE) T2 sequence
27 with a
volume coil and the following parameters: echo time
15.9 ms, repetition time 3,425 ms, field of view 6 3
4.13 cm2, matrix size 465 3 256, rare factor of 8, and
an acquisition time of 5 minutes.
We intentionally sacrificed MRI quality to achieve a fast
MRI acquisition on animals that had already spent 1.5 to
2 hours under anesthesia while the SPECT image was
acquired. To prevent any animal displacement between
modalities, MRI was performed without any animal vital
sign monitoring (respiration, electrocardiography, or tem-
perature). This prevented us from acquiring a respiratory
gated study, which would have improved quality by
reducing breathing artifacts.
SPECT/MRI Coregistration
The spatial rigid transformation to align MRI to SPECT
images21 was obtained by segmenting the capillaries,
adjusting each capillary to a line, and matching the
corresponding fiducials of both modalities following a
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method proposed by Pascau and colleagues,28 which was
based on minimizing the distance between corresponding
segments of lines.
Semiquantitative Image Analysis
On the MRIs, regions of interest (ROI) were selected over
the entire volume of the tumor and abdomen (five circular
sections of 3 mm diameter) at each time point (Figure S1,
online version only). These ROI were applied to the
SPECT images to obtain the mean activity values of the
entire volume of the ROI. Activity values were corrected
for the radioactive decay.
111In Distribution by Organ
Organ activity was measured directly in two control animals
and five hMSC-injected animals after the last imaging
session. The animals were sacrificed, and organs, including
the liver, lungs, kidneys, long bones (tibia and femur),
testicles, and spleen, were harvested. These organs were
weighed, and the activity was measured at the 111In
photopeak in a well counter (Wallac Wizard 1480 counter,
PerkinElmer, Spain). Lung uptake was used as a reference
for calculating the relative specific activity of each organ.
Real-Time Quantitative Polymerase Chain Reaction
Real-time quantitative polymerase chain reaction (RT-
qPCR) was used to confirm homing of the inoculated
hMSCs in the neuroblastoma. Tumors were harvested and
frozen from one control and two hMSC-injected animals
after the last imaging session. Total ribonucleic acid (RNA)
was isolated using the TRIzol method, according to the
manufacturer’s protocol (Life Technologies, Spain), and
2 mg was converted into complementary DNA (cDNA)
using M-MLV Reverse Transcriptase (Life Technologies)
with oligo dT primers. RT-qPCR was performed using the
LightCycler 480 SYBR Green I Master (Roche Applied
Science, Spain) with the primers listed below and analyzed
using the LightCycler System (Roche Applied Science). The
sequences for the human vimentin and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) primers are as follows:
vimentin, forward, TGTCCAAATCGATGTGGATGTTTC,
and TTGTACCATTCTTCTGCCTCCTG reverse; GAPDH,
forward GCCAAGGTCATCCATGACAACT, and reverse
AGGGCCATCCACAGTCTTCTG. Three replicates were
performed per cDNA sample along with ‘‘no template’’
controls. The specificity of amplification was confirmed
by melting curve analysis. GAPDH expression was
selected as a housekeeping gene and used as an internal
control for normalization of vimentin messenger RNA
expression.
Statistical Analysis
Differences in tumor uptake between the experimental
groups were assessed by linear mixed-model analysis of
variance. Data for organ activity distribution were
compared using Student t-test. Differences were consid-
ered statistically significant for p , .05.
Results
Cell Labeling Efficiency
Incubation of hMSCs with PBS containing 10 Bq/cell of
111In-oxine for 20 minutes resulted in a mean 6 standard
deviation labeling efficiency of 71.5 6 10.6%. The activity of
1 million cells was 3.3 6 1.4 MBq. Trypan blue staining
showed a survival of 80% immediately after labeling. We had
previously tested labeling using other radiotracers with a
shorter half-life, namely, FDG and 99mTc-HMPAO.17,29
Although FDG and 99mTc-HMPAO showed higher cell
viability than 111In-oxine (93%, 88% and 80%, respectively),
hMSCs labeling efficiency with these two radiotracers was
lower (18.5% for FDG and 44.4% for 99mTc-HMPAO)
compared with the labeling efficiency achieved with 111In-
oxine (72%).
Evidence of Homing of hMSCs to the Tumor
SPECT and MRI images were acquired 24 and 48 hours after
intraperitoneal administration of 111In-labeled hMSCs or
administration of free 111In-oxine (controls). In MRI,
abdominal structures are visible and the tumor is easily
identified. In SPECT, however, the lack of anatomic
references makes it almost impossible to locate the tumor
area and detect specific uptake. After multimodality fusion,
activity from the tumor area can be separated from the
background thanks to the ROI drawn on the MRI. Figure 1
shows coronal and axial views of the fusion of registered
SPECT and MRI images of an hMSC-injected animal and a
control animal. At both time points, the images showed
similar activity in the abdomen in both controls and hMSC-
injected animals. In general, abdominal activity decreases at
48 hours (Figure 2A). hMSC-injected animals showed
increased uptake in the tumor area at 48 hours (p 5 .02),
whereas the control group showed a low level of activity
at 24 hours (possibly just reflecting spillover from the
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abdominal cavity), which decreased at 48 hours (Figure 2B).
The uptake percentage in the tumor area at 48 hours was
higher in hMSC-injected animals than in controls.
111In Organ Distribution
Organs were harvested immediately following the last scan,
and activity was measured for 2 minutes; activity in each
organ was corrected for organ weight and the decay factor.
We used lung uptake as a reference value for calculating
the relative specific activity of each organ. Forty-eight
hours after injection, a number of cells seemed to be
trapped in the liver and bone marrow, thus reducing the
available number of homing cells (Figure S2, online
version only). No significant difference in the distribution
of activity was observed between controls and hMSC-
injected animals.
Vimentin Expression
Our results revealed that the mesenchymal marker vimentin
was expressed 4.5 6 1.2 (mean 6 SD) times more in the
tumor tissue obtained from the hMSC-injected animals
than in the tumor samples obtained from the control
animals, indicating the presence of these cells. Control
animals showed only mouse vimentin expression.
Discussion
In the present study, we developed a mouse model based on
the neuroblastoma cell line NB-1691 to mimic the scenario
used by Garcia-Castro and colleagues.7 Although these
authors reported a reduction in tumor metastasis in patients
after infusion of adenovirus-infected hMSCs, they were not
able to confirm hMSC tumor homing. We demonstrated
that 111In-labeled human bone marrow–derived MSCs
can home to neuroblastoma within 24 to 48 hours of
intraperitoneal administration; to our knowledge, this work
constitutes the first in vivo validation of such a hypothesis.
We also showed that the multimodality approach, SPECT-
MRI, is essential when localizing hMSCs.
The main criterion for choosing 111In-oxine as a tracer in
this study was its long half-life, which allowed us to track cells
for up to 48 hours. We did not assess proliferation and
Figure 1. Coregistered MRI/SPECT
images. Coronal and axial views
of spatially coregistered MRI/SPECT
images at 48 hours after intraperito-
neal administration of 111In-oxine
labeled human mesenchymal stem
cells (hMSCs) or free 111In-oxine.
Significant activity can be observed
in the abdomen of both animals.
A, The tumor in the control animal
shows scant 111In activity. B, In the
hMSC-injected animal, uptake can be
observed inside the tumor area (white
arrows).
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differentiation because in the cited clinical trial, hMSCs were
used as a vehicle to deliver adenovirus,7 whose replication
cycle kills the hMSCs in 48 to 72 hours. Furthermore, several
authors detected no hMSC damage at the dose we used (10 Bq
per cell) within the first 48 hours after labeling.2,15
Gholamrezanezhad and colleagues found that the effect of
111In-oxine on hMSC viability is both time and dose
dependent.30 They reported a viability reduction of about
10% 48 hours after labeling with a dose of 7.16 MBq/106cells,
almost two times the dose we used in our study (3.3 6
1.4 MBq/106cells). In contrast, other authors reported cell
damage 48 hours after labeling murine hematopoietic
progenitor cells even at low doses (0.1 MBq/106cells).31,32 In
summary, these studies show that cell damage induced by
111In labeling depends on both dose and cell type. Our results
showed that labeling hMSCs with a dose of 10 Bq/cell of 111In-
oxine does not destroy cell migration mechanisms within the
first 48 hours. Although our hMSC viability immediately after
labeling was reduced (80%), this may have been due to several
causes besides 111In damage. It is well known that freezing and
defrosting induce some cell damage. The mean cell viability
just after defrosting has been previously reported to be about
85%.33,34 Furthermore, our labeling protocol led to an
additional cell viability reduction of 3% due to washes and
centrifugations (data not shown).
We incidentally observed that the use of thawed cells
increased labeling efficiency from 52% to about 72%,
probably because we avoided cell detachment from the
flask before incubation with 111In-oxine. To confirm this
finding, it would be necessary to further investigate
differences in labeling efficiency between cultured and
thawed cells using the same number of cell passages and
the same hMSC donor.
Although the intraperitoneal route should ensure that
all activity detected in the tumor was caused by migration
of hMSCs, the activity from the testicles and abdomen was
too close to the tumor area and produced an inconvenient
spillover that hampered image interpretation. Kraitchman
and colleagues found similar problems when they studied
cell migration in animals with myocardial infarction.20 For
this reason, the availability of an MRI anatomic template
proved to be critical for properly identifying the different
regions. The time dynamics of ROI activity ensured that
uptake was indeed due to hMSC tumor homing as 111In
activity in the tumor 48 hours after administration
increased in only six of seven hMSC-injected animals
and decreased in controls. Although neither radiolabeling
nor MRI labeling can discriminate live from dead cells,35
our findings suggest that some hMSCs homed to the
tumor within 24 to 48 hours after administration, meaning
that hMSCs were alive in this time window. Although
hMSC homing may be visualized a few hours after
transplantation,36 their final number in the target area
depends on both time and the administration route.
Barbash and colleagues reported that less than 1% of the
cells migrated to the target area 4 hours after injection in
the left ventricular cavity, whereas after intravenous
administration, cell migration was four times lower at
the same time.37 Systemic administration is known to
require a longer time window to enable visualization of cell
homing.31 For these reasons, we decided to acquire the
images 24 and 48 hours after administration.
In our work, SPECT findings were corroborated by RT-
qPCR results. Due to its high sensitivity, RT-qPCR has
proven crucial in some clinical trials to detect transplanted
MSC-specific signals.38,39 hMSC-injected animals showed
higher vimentin expression than control animals. Although
NB-1691 is a human line, after implantation, tumors are
infiltrated with multiple mouse cell types, including
fibroblasts and MSCs. Control tumors showed some degree
of vimentin expression, probably owing to infiltration by
Figure 2. Abdominal and tumor uptake measurements. Regions of
interest (ROI) were selected in the MRI over the tumor and abdomen
at each time point and applied to the SPECT images. Uptake at 48
hours is represented as a percentage of uptake at 24 hours (dotted line).
A, In general, abdominal uptake decreases 48 hours after injection.
B, Increased uptake was observed in the tumors of six of seven human
mesenchymal stem cell (hMSC)-injected animals 48 hours after
administration (dark bars), whereas activity in the control tumors
decreased about 50%.
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mouse cells and the fact that human and mouse vimentin
genes are highly homologous, thus making it difficult to
design specific primers for each gene. Validation of
vimentin primers used in this study was previously carried
out in our laboratory as an internal control (data not
shown). However, the higher level of vimentin expression in
tumors obtained from hMSC-injected animals could be
explained only by the fact that hMSCs migrated from the
peritoneal cavity and homed to these tumors.
In the present study, hMSCs were injected intraperito-
neally to avoid accumulation in the lungs because these cells
are relatively large and express adhesion molecules.37,40 Our
approach is supported by several previous works. Gao and
colleagues reported that rat MSCs labeled with 111In-oxine
accumulated primarily in the lungs and liver 15 minutes
after intravenous or intra-arterial administration, whereas
after intraperitoneal administration, activity appeared in the
liver, testicles, spleen, and kidneys.14 Similar results were
reported by Rosado-de-Castro and colleagues 24 hours after
intravenous or intra-arterial administration of 99mTc-labeled
hMSCs in patients.41 Cell trapping by the reticuloendothelial
system seems to be the major cause of hMSC loss, regardless
of the administration method, because it comprises
phagocytic cells capable of engulfing and ingesting foreign
cells and bacteria, as reported elsewhere.42 We also observed
high 111In activity in the testicular area in some animals 48
hours after administration and found this activity to be
similar to that of the kidneys and higher than that of the liver
(see Figure S2, online version only). We cannot be sure
whether the cells trapped in these organs were dead or alive.
It is possible that in some organs, such as the liver, both
situations coexist. Brenner and colleagues reported an
increased uptake in liver and kidney due to 111In released
from the cells over time.31 Although radiolabeling cannot
discriminate live from dead cells, the 111In organ uptake
found in our work is consistent with previous litera-
ture.13,37,41 These organs have been identified as the major
site for homing of immunocompetent cells.31 Nevertheless,
bioluminescent MSC studies showed cell migration to the
liver and spleen 24 hours after intravenous administration.
Images after intraperitoneal administration indicated initial
dissemination throughout the peritoneal cavity, followed by
specific localization on day 7 in tumor-bearing animals and
disappearance in control animals. On day 14, biolumines-
cent activity was localized only to sites of visible tumor.43
Clinical neuroblastoma most frequently originates in
one of the adrenal glands and also develops in nerve tissues
in the neck, chest, abdomen, or pelvis. The most typical
sites of neuroblastoma metastasis are bone marrow and
bone. Specifically, the incidence of metastatic sites at
neuroblastoma diagnosis is 70% in bone marrow, 55%
in bone, 31% in lymph nodes, 29% in liver, 18% in
intracranial and orbital sites, 3.5% in lung, and 0.5% in the
central nervous system.44,45 The tumor of our xenograft
model was far below the high nonspecific uptake showed
in Figure 1, which may hamper hMSC migration in
patients with abdomen or pelvis lesions. However, bone
marrow and bone do not suffer as much from the problem
of nonspecific signal. Thus, the combination of techniques
proposed in this article may have a clinical application in
most cases of neuroblastoma metastasis, although not in
all patients, due to the areas with the nonspecific uptake
problems cited above.
After intraperitoneal administration, it is possible that
liquid flows inside the peritoneal cavity and accumulates in
the scrotum. Combined with reticuloendothelial retention,
this accumulation could further reduce the number of
hMSCs able to home to the tumor. The results of cardiac
animal studies show that only 1% of intravenously injected
stem cells home to the heart; however, this amount can
increase to 2% if cells are injected into the left ventricular
cavity.37 Hofmann and colleagues found similar results
after intracoronary delivery of FDG-labeled bone marrow
cells in patients with acute myocardial infarction, although
no myocardial activity was observed after intravenous
administration.36 As mentioned above, we selected intra-
peritoneal administration of hMSCs to reduce or prevent
lung cell trapping, as would occur with intravenous
administration. Although intra-arterial administration also
avoids lung trapping, it has been reported that it may lead to
microvascular occlusions,46 which may compromise the
survival of the subject under study and might also attract the
hMSCs, perhaps biasing the study. On the other hand,
intraperitoneal administration produced high accumulation
of cells in the peritoneal cavity and led to an inconvenient
spillover into the tumor area. Perhaps injection of cells into
the left ventricular cavity would be a better choice for future
work because lung retention is also reduced and the number
of cells able to migrate and colonize injured tissue is
expected to be higher than with intravenous routes.37
However, the main drawback of the left ventricular cavity
administration is that it requires very specific techniques
(such as echocardiography) to guide the procedure and
involves significant survival risk in small animals.
In our study, each animal received around 3.3 6
1.4 MBq of 111In-oxine per million cells, which is usually the
lowest amount of cells injected for clinical therapeutic
studies and almost the minimum 111In activity required in
pediatric studies (patients less than 1 year old), thus making
it possible to transfer this approach to clinical research.
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Our study was limited by the small sample size, which
does not enable a proper statistical analysis. This is the
reason why in this work we do not emphasize the statistical
analysis: the principal results are based on the image
interpretation and semiquantitative results. No attempt was
performed to calculate absolute activity values for two
reasons: (1) peritoneal uptake differed greatly from animal
to animal, and this prevented us from choosing any
common reference region or organ, and (2) in contrast to
PET, it is almost impossible to obtain reliable calibration
factors in SPECT.47 In addition, the use of cells from
different donors introduces a certain degree of variability
owing to possible differences in migration activity and
labeling efficiency. Although our multimodal bed system
worked properly for this mouse model, we cannot guarantee
the absence of slight organ movements. Also, the quality of
111In imaging is affected by the fact that it has two
photopeaks (171 and 245 keV) because higher energy
radiation is more difficult to collimate. Finally, given the
small number of hMSCs that homed to the tumor, RT-
qPCR was chosen as a validation method because it is a
quantitative method and more sensitive than histology.
In conclusion, we were able to detect homing of hMSCs
to a neuroblastoma at 24 and 48 hours in a mouse model
using coregistration of SPECT and MRI images, which
proved to be essential. Our results were confirmed by RT-
qPCR. The procedure can be used to monitor cell therapy
provided that the activity of 111In-labeled hMSCs does not
exceed the limits established for pediatric patients.
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Figure S2. Relative organ activity distribution by group. Relative
activity expressed as mean 6 standard deviation of organs in control
and human mesenchymal stem cell (hMSC)-injected animals 48 hours
after intraperitoneal administration of free 111In-oxine or 111In-oxine–
labeled hMSCs.
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SUPPLEMENTARY MATERIAL
Figure S1. Example of region of
interest (ROI) delineations on the
coregistered MRI/SPECT images. Left
to right: coronal and axial view of the
tumor (blue ROI) and coronal view of
the abdomen (red ROI). hMSC 5
human mesenchymal stem cell.
